Factory Mutual Insurance Co. cut its holdings in Celgene Co. (NASDAQ:CELG) by 4.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 695,700 shares of the biopharmaceutical company’s stock after selling 30,800 shares during the period. Factory Mutual Insurance Co.’s holdings in Celgene were worth $72,603,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Thompson Davis & CO. Inc. grew its holdings in Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 43 shares during the period. Arcadia Investment Management Corp MI grew its holdings in Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 400 shares during the period. Robecosam AG bought a new position in Celgene during the third quarter valued at $114,000. Guidant Wealth Advisors bought a new position in Celgene during the third quarter valued at $119,000. Finally, Capital Bank & Trust Co grew its holdings in Celgene by 166.8% during the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 517 shares during the period. 78.10% of the stock is owned by institutional investors.

Shares of Celgene Co. (NASDAQ CELG) opened at $91.98 on Wednesday. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29. Celgene Co. has a 12-month low of $88.32 and a 12-month high of $147.17. The stock has a market capitalization of $68,831.59, a price-to-earnings ratio of 13.34, a price-to-earnings-growth ratio of 0.64 and a beta of 1.49.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The company had revenue of $3.48 billion for the quarter, compared to the consensus estimate of $3.46 billion. During the same quarter last year, the business posted $1.61 earnings per share. The firm’s revenue was up 16.9% compared to the same quarter last year. sell-side analysts forecast that Celgene Co. will post 7.68 EPS for the current year.

In other Celgene news, insider Mark J. Alles acquired 3,260 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were bought at an average price of $91.90 per share, for a total transaction of $299,594.00. Following the completion of the transaction, the insider now owns 178,904 shares of the company’s stock, valued at approximately $16,441,277.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.95% of the company’s stock.

Several equities analysts have weighed in on CELG shares. UBS Group reduced their price objective on Celgene from $153.00 to $146.00 and set a “buy” rating for the company in a report on Friday, October 20th. Stifel Nicolaus reduced their price objective on Celgene from $155.00 to $149.00 and set a “buy” rating for the company in a report on Friday, October 20th. Leerink Swann reissued a “buy” rating and set a $156.00 price objective on shares of Celgene in a report on Friday, October 20th. Oppenheimer reissued a “buy” rating and set a $170.00 price objective on shares of Celgene in a report on Friday, October 20th. Finally, Wells Fargo & Co reissued a “buy” rating and set a $163.00 price objective on shares of Celgene in a report on Friday, October 20th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the company’s stock. Celgene has an average rating of “Buy” and a consensus price target of $130.35.

COPYRIGHT VIOLATION WARNING: “Celgene Co. (CELG) Stake Lessened by Factory Mutual Insurance Co.” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://theolympiareport.com/2018/02/14/celgene-co-celg-stake-lessened-by-factory-mutual-insurance-co.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.